$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
New breakthrough in targeted treatment of KRAS mutated lung cancer: detailed analysis of Adagrasib efficacy, price and drug purchase guide
2026-02-01 22:25:32
Check Details
Can Alpelisib be used alone?
2026-02-01 22:25:32
Check Details
Conditions for medical insurance reimbursement of fostatinib/fotantinib
2026-02-01 22:25:32
Check Details
Introduction to the main indications of Serputinib/Serpatinib (Ruitu)
2026-02-01 22:25:32
Check Details
The latest market price reference for lenvatinib/lenvatinib in 2026
2026-02-01 22:25:32
Check Details
What are the specific contraindications of Besudil/Yilaike and what should be paid attention to when using it?
2026-02-01 22:25:32
Check Details
Is Brivaracetam better to take before or after meals?
2026-02-01 22:25:32
Check Details
Price and effectiveness analysis of the Indian version of Alpelisib
2026-02-01 22:25:32
Check Details
Fostatinib/Fotantinib combination regimen
2026-02-01 22:25:32
Check Details
Clinical effect of serputinib/serpatinib (Ruitu) in the treatment of lung cancer
2026-02-01 22:25:32
Check Details
Lenvatinib/lenvatinib (Lenvima) standard usage and dosage guidelines
2026-02-01 22:25:32
Check Details
How long is it generally recommended to take Besudil/Yilaike and how to judge the efficacy?
2026-02-01 22:25:32
Check Details
1
2
...
2312
2313
2314
2315
2316
2317
2318
...
2440
2441
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Daraxonrasib, Marking Milestone in Metastatic Pancreatic Cancer Treatment
2
FDA Approves Zanidatamab (Ziihera): HER2 Bispecific Antibody Plus Immunotherapy for First-Line Gastric Cancer
3
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
4
FDA Approves Tauklarify for Tau PET Imaging in Alzheimer's Disease Assessment
5
First CELMoD Drug Zenbexus Wins FDA Accelerated Approval for Multiple Myeloma
6
FDA Approves First mRNA Flu Vaccine mFLUSIVA
7
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
8
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
9
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
10
Global Oncology Update: Breakthroughs in Advanced Cancer Survival and Novel Therapies
11
Phase 1 Study Progress of Ceralasertib in Combination with Durvalumab for Advanced NSCLC and HNSCC
12
Global Breakthroughs in Cancer Drugs and Advanced Treatment Technologies